drugset / Trial / NCT07289464

A Clinical Study of RSS0343 in Healthy Subjects

NCT07289464

Phase 1 Recruiting 48 enrolled Reistone Biopharma Company Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT/QTc interval.

Timeline

Start
2026-01-04
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject RSS0343 Unknown Oral

Indications